Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
33.16
+0.89 (2.76%)
Real-time:   2:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.50 - 33.40
52 week 14.83 - 63.73
Open 32.33
Vol / Avg. 1.42M/2.24M
Mkt cap 1.80B
P/E     -
Div/yield     -
EPS -2.64
Shares 54.96M
Beta 1.48
Inst. own 76%
Jul 17, 2017
Q2 2017 Sarepta Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 27, 2017
Sarepta Therapeutics Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 6, 2017
Sarepta Therapeutics Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 31, 2017
Sarepta Therapeutics Inc at Boston Biotech Boston CEO Conference - 3:20PM EDT - Add to calendar
Apr 27, 2017
Q1 2017 Sarepta Therapeutics Inc Earnings Call - Webcast
Apr 27, 2017
Q1 2017 Sarepta Therapeutics Inc Earnings Release
Mar 8, 2017
Sarepta Therapeutics Inc at Cowen Health Care Conference
Feb 28, 2017
Q4 2016 Sarepta Therapeutics Inc Earnings Call - Webcast
Feb 28, 2017
Q4 2016 Sarepta Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 514.56% -4930.18%
Operating margin -240.15% -4920.31%
EBITD margin - -4816.81%
Return on average assets 72.10% -76.59%
Return on average equity 88.08% -101.42%
Employees 197 -
CDP Score - -

Address

215 1st St Ste 415
CAMBRIDGE, MA 02142-1213
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Officers and directors

Edward M. Kaye M.D. Director
Age: 68
Bio & Compensation  - Reuters
Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer
Age: 52
Bio & Compensation  - Reuters
David Tyronne Howton Jr. Senior Vice President, General Counsel, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Alexander Cumbo Senior Vice President, Global Commercial Development
Age: 46
Bio & Compensation  - Reuters
Shamim Ruff Senior Vice President - Regulatory Affairs and Quality
Age: 57
Bio & Compensation  - Reuters
Catherine Stehman-Breen M.D. Senior Vice President, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Richard J. Barry Independent Director
Age: 58
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Claude Nicaise M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters